Wells Fargo
MLYS icon

Wells Fargo’s Mineralys Therapeutics MLYS Stock Holding History

Wells Fargo’s Portfolio MLYS Stock Details MLYS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$1.78M Buy
66,057
+39,976
+153% +$1.1M ﹤0.01% 3706
2026
Q1 		$707K Sell
26,081
-30,675
-54% -$900K ﹤0.01% 3952
2025
Q4 		$2.06M Buy
56,756
+26,702
+89% +$1.07M ﹤0.01% 3407
2025
Q3 		$1.14M Sell
30,054
-1,703
-5% -$36.8K ﹤0.01% 3728
2025
Q2 		$430K Buy
31,757
+4,874
+18% +$70.6K ﹤0.01% 4253
2025
Q1 		$427K Buy
26,883
+3,169
+13% +$36.5K ﹤0.01% 4209
2024
Q4 		$292K Buy
23,714
+3,802
+19% +$49.7K ﹤0.01% 4549
2024
Q3 		$241K Buy
19,912
+221
+1% +$2.67K ﹤0.01% 4457
2024
Q2 		$230K Buy
19,691
+5,268
+37% +$66.3K ﹤0.01% 4428
2024
Q1 		$186K Buy
14,423
+6,405
+80% +$79.1K ﹤0.01% 4513
2023
Q4 		$69K Buy
8,018
+3,083
+62% +$24.2K ﹤0.01% 5130
2023
Q3 		$46.9K Sell
4,935
-1,388
-22% -$18.1K ﹤0.01% 5213
2023
Q2 		$108K Buy
6,323
+3,987
+171% +$59.6K ﹤0.01% 4989
2023
Q1 		$36.6K Buy
+2,336
New +$39.3K ﹤0.01% 5333

Other funds holding MLYS

CP
Catalys Pacific Tokyo, Japan $229M AUM 100.3% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
SB
Samsara BioCapital Palo Alto, California $1.22B AUM 242.83% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
DM
Deerfield Management New York $9.59B AUM 113.36% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
LCM
Laurion Capital Management New York $3.9B AUM 75.03% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

Wells Fargo's MLYS Position: Q2 2026 in Review

Wells Fargo increased its Mineralys Therapeutics (MLYS) stake by 153% in Q2 2026, buying an estimated $1.1M and bringing the position to 66,057 shares worth $1.78M. The position accounts for ﹤0.01% of the portfolio, ranked #3706.

Wells Fargo first reported a position in MLYS in Q1 2023 and has held it in 14 quarters since. The position peaked at $2.06M in Q4 2025. 225 funds tracked by Wall St. Rank hold MLYS as of Q2 2026.

  • Wells Fargo held 66,057 shares of Mineralys Therapeutics worth $1.78M as of Q2 2026.
  • Wells Fargo bought 39,976 Mineralys Therapeutics shares in Q2 2026, an estimated $1.1M.
  • Mineralys Therapeutics made up ﹤0.01% of Wells Fargo's portfolio in Q2 2026, its #3706 holding.
  • Wells Fargo first reported a position in Mineralys Therapeutics in Q1 2023 and has held it in 14 quarters since.
  • Wells Fargo's Mineralys Therapeutics position peaked at $2.06M in Q4 2025.
  • 225 funds tracked by Wall St. Rank held Mineralys Therapeutics as of Q2 2026.

Based on Wells Fargo's 13F filing for Q2 2026, filed 14 Aug 2026.